Q4 26 EPS
$0.26
MISS 7.93%
Est. $0.28
Q4 26 Revenue
$145.4M
BEAT +1.02%
Est. $143.9M
vs S&P Since Q4 26
-16.6%
TRAILING MARKET
DOCS -17.0% vs S&P -0.5%
Full Year 2026 Results
FY 26 EPS
$1.52
MISS 1.72%
Est. $1.55
FY 26 Revenue
$644.9M
BEAT +0.20%
Est. $643.5M
Market Reaction
Did DOCS Beat Earnings? Q4 2026 Results
Doximity delivered a mixed fiscal Q4 2026, posting revenue of $145.37 million, up 5.1% year-over-year and edging past the $143.91 million consensus by 1.01%, yet falling short on the bottom line with earnings per share of $0.26 against the $0.28 esti… Read more Doximity delivered a mixed fiscal Q4 2026, posting revenue of $145.37 million, up 5.1% year-over-year and edging past the $143.91 million consensus by 1.01%, yet falling short on the bottom line with earnings per share of $0.26 against the $0.28 estimate, a miss of 7.93% that ended the company's four-consecutive-quarter EPS beat streak. The primary culprit was a sharp surge in stock-based compensation, which doubled to $36.74 million from $18.06 million a year ago, compressing GAAP net income to $19.11 million from $62.46 million and squeezing adjusted EBITDA margins to 45.3% from 50.4%. Beaten-down heading into the print, the stock faces fresh scrutiny as full-year FY2027 guidance of $664 million to $676 million in revenue implies roughly 4-5% growth, a notable deceleration from FY2026's 13% expansion, though management pointed to a record 800,000 active prescribers and rapid clinical AI adoption as reasons for optimism looking ahead.
Key Takeaways
- • Engagement record of over 800,000 active prescribers using workflow tools in Q4
- • Strong clinical AI adoption with nearly half of active prescribers using AI tools
- • Rapid growth in AI prompt usage with prompts per user nearly doubling January to April
- • Operating cash flow growth of 11% year-over-year in Q4
- • Free cash flow growth of 11% year-over-year in Q4
DOCS Forward Guidance & Outlook
For Q1 FY2027 (quarter ending June 30, 2026), Doximity expects revenue of $151 million to $152 million and adjusted EBITDA of $68.5 million to $69.5 million. For full fiscal year 2027 (ending March 31, 2027), the company guides revenue of $664 million to $676 million and adjusted EBITDA of $323 million to $335 million.
DOCS YoY Financials
Q4 2026 vs Q4 2025, source: SEC Filings
DOCS Revenue by Segment
Business unit performance breakdown
“We're thrilled to announce that we reached a new engagement record of over 800,000 active prescribers using our workflow tools in Q4. Nearly half of those providers used our clinical AI last quarter, while our prompts per user nearly doubled from January to April alone.”
— Jeff Tangney, Q4 2026 Earnings Press Release
DOCS Earnings Trends
DOCS vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
DOCS EPS Trend
Earnings per share: estimate vs actual
DOCS Revenue Trend
Quarterly revenue: estimate vs actual
DOCS Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 26 MISS FY | $0.28 | $0.26 | -7.93% | $145.4M | +1.02% |
| FY Full Year | $1.55 | $1.52 | -1.72% | $644.9M | +0.20% |
| Q3 26 BEAT | $0.45 | $0.46 | +2.89% | $185.1M | +1.93% |
| Q2 26 BEAT | $0.38 | $0.45 | +18.70% | $168.5M | +6.94% |
| Q1 26 BEAT | $0.31 | $0.36 | +17.23% | $145.9M | +4.57% |
| Q4 25 BEAT FY | $0.27 | $0.38 | +39.25% | $138.3M | +3.20% |
| FY Full Year | $1.31 | $1.42 | +8.41% | $570.4M | +0.15% |